This preprint is under consideration at Supportive Care in Cancer. A preprint is a preliminary version of a manuscript that has not completed peer review at a journal. Research Square does not conduct peer review prior to posting preprints. The posting of a preprint on this server should not be interpreted as an endorsement of its validity or suitability for dissemination as established information or for guiding clinical practice.
Learn more about In Review
Research Article
Jonas DUBU
ILC Centre Jean Bernard / Elsan clinique Victor Hugo
Corresponding Author
ORCiD: https://orcid.org/0000-0001-9662-7171
License:
This work is licensed under a CC BY 4.0 License. Read Full License
Background
Prognostic factors can impact the quality of life and overall survival in metastatic situations: sarcopenia and nutritional status disorders.
Methods
We conducted a non-interventional, observational prospective study during 3 consecutive months (SPACE trial, ClinicalTrials.gov identifier: NCT04714203). Performance status, lumbar skeletal muscle index (by CT scan), albumin, C-reactive protein, or LDH, were collected from medical records in the classic balance sheet at inclusion and then at 3 and 6 months after the day of inclusion.
Results
38 patients were included with a median age of 68 years old and 31 were evaluable for sarcopenia. 58.1% of patients with metastatic cancer were sarcopenic at the diagnosis and 61% at 6 months. At the inclusion, 87.5% of sarcopenic patients were men (p < 0.0002) and sarcopenia status was associated with lung localization (p < 0.0332) and non-operable cancer (p < 0.0069).
Conclusion
The majority of patients in our study were sarcopenic at the inclusion and at 6 months. However, the number of patients was too small to correlate sarcopenia with survival. Further larger studies are needed to establish stronger results. In the future, sarcopenic patients could benefit from specialized care with nutrition and adapted physical activity.
Keywords
sarcopenia, cancer, palliative care
Figure 1
Figure 2
Figure 3
Figure 4
This is a list of supplementary files associated with this preprint. Click to download.
Loading...
Badges
Prescreen
This manuscript passed our Prescreen assessment
Complete author information
Appropriate declaration statements
Potential risks to human health
Prescreen
Peer Review Timeline
CURRENT STATUS: Under Review
Version 1
Posted 11 Mar, 2021
No community comments so far
Review #? received
Received 07 Mar, 2021
Reviewers invited
Invitations sent on 07 Mar, 2021
Editor assigned
On 16 Feb, 2021
First submitted
On 10 Feb, 2021
Metrics
Comments: 0
PDF Downloads: ...
HTML Views: ...
Learn more about our company.
This preprint is under consideration at Supportive Care in Cancer. A preprint is a preliminary version of a manuscript that has not completed peer review at a journal. Research Square does not conduct peer review prior to posting preprints. The posting of a preprint on this server should not be interpreted as an endorsement of its validity or suitability for dissemination as established information or for guiding clinical practice.
Learn more about In Review
Research Article
Jonas DUBU
ILC Centre Jean Bernard / Elsan clinique Victor Hugo
Corresponding Author
ORCiD: https://orcid.org/0000-0001-9662-7171
Badges
Prescreen
This manuscript passed our Prescreen assessment
Complete author information
Appropriate declaration statements
Potential risks to human health
Prescreen
Peer Review Timeline
CURRENT STATUS: Under Review
Version 1
Posted 11 Mar, 2021
No community comments so far
Review #? received
Received 07 Mar, 2021
Reviewers invited
Invitations sent on 07 Mar, 2021
Editor assigned
On 16 Feb, 2021
First submitted
On 10 Feb, 2021
License:
This work is licensed under a CC BY 4.0 License. Read Full License
Background
Prognostic factors can impact the quality of life and overall survival in metastatic situations: sarcopenia and nutritional status disorders.
Methods
We conducted a non-interventional, observational prospective study during 3 consecutive months (SPACE trial, ClinicalTrials.gov identifier: NCT04714203). Performance status, lumbar skeletal muscle index (by CT scan), albumin, C-reactive protein, or LDH, were collected from medical records in the classic balance sheet at inclusion and then at 3 and 6 months after the day of inclusion.
Results
38 patients were included with a median age of 68 years old and 31 were evaluable for sarcopenia. 58.1% of patients with metastatic cancer were sarcopenic at the diagnosis and 61% at 6 months. At the inclusion, 87.5% of sarcopenic patients were men (p < 0.0002) and sarcopenia status was associated with lung localization (p < 0.0332) and non-operable cancer (p < 0.0069).
Conclusion
The majority of patients in our study were sarcopenic at the inclusion and at 6 months. However, the number of patients was too small to correlate sarcopenia with survival. Further larger studies are needed to establish stronger results. In the future, sarcopenic patients could benefit from specialized care with nutrition and adapted physical activity.
Figure 1
Figure 2
Figure 3
Figure 4
Loading...